DelveInsight’s, “Rosacea - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Rosacea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Rosacea Understanding
Rosacea: Overview
Rosacea is a chronic skin disease that affects more than 16 million Americans. The cause of rosacea is still unknown, and there is no cure. However, research has allowed doctors to find ways to treat the condition by minimizing its symptoms. There are four subtypes of rosacea. Each subtype has its own set of symptoms. It is possible to have more than one subtype of rosacea at a time. Rosacea’s trademark symptom is small, red, pus-filled bumps on the skin that are present during flare-ups. Typically, rosacea affects only skin on your nose, cheeks, and forehead. Flare-ups often occur in cycles.

"Rosacea - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Rosacea pipeline landscape is provided which includes the disease overview and Rosacea treatment guidelines. The assessment part of the report embraces, in depth Rosacea commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Rosacea collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Rosacea R&D. The therapies under development are focused on novel approaches to treat/improve Rosacea.
• In September 2020, Sol-Gel Technologies announced that its New Drug Application (NDA) for Epsolay (benzoyl peroxide), an investigational proprietary topical cream for the treatment of inflammatory lesions of rosacea, containing 5% encapsulated benzoyl peroxide, has been accepted for filing by the U.S. Food and Drug Administration (FDA).
• In February 2020, Foamix Pharmaceuticals Ltd. announced the publication of the Company's Phase 3 studies FX2016-11 and FX2016-12 (Studies 11 & 12) in the Journal of the American Academy of Dermatology (JAAD). Studies 11 and 12 were conducted by Foamix to support the New Drug Application (NDA) submission of FMX103 (minocycline, 1.5% foam), which is currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe papulopustular rosacea in adults.

Rosacea Emerging Drugs Chapters
This segment of the Rosacea report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Rosacea Emerging Drugs
• BMX 010: BioMimetix
BMX 010, a mangano porphyrin antioxidant mimetic is being developed by BioMimetix, under a license from Duke University, for the treatment of Rosacea. The drug is currently in phase II stage of development.
Further product details are provided in the report……..

Rosacea: Therapeutic Assessment
This segment of the report provides insights about the different Rosacea drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Rosacea
There are approx. 30+ key companies which are developing the therapies for Rosacea. The companies which have their Rosacea drug candidates in the most advanced stage, i.e. Phase III include, Cutanea Life Sciences.
• Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Rosacea pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

• Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Rosacea: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Rosacea therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Rosacea drugs.

Rosacea Report Insights
• Rosacea Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Rosacea Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Rosacea drugs?
• How many Rosacea drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rosacea?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Rosacea therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Rosacea and their status?
• What are the key designations that have been granted to the emerging drugs?